“I can say it pretty confidently now that if you have a KRas mutation driven disease, I can almost guarantee you a stable disease or better on Reolysin ... it doesn't matter what it is ... Pancreatic ... non-small cell lung, Colorectal,”
and then project the potential of ONCY’s value when that is proven to the market. Flying will be vastly understating its movement.
I am a scientist wrote:"... then the September effect was due entirely to Reolysin"
Are you aware that in cc's Brad has said that he does not know why the mets group has longer PFS? He suggested the condition of patients in the trial could be the reason, or that treatment w an addl chemo agent could be the reason.
When asked directly by an analyst if Reo was the reason, he flat out said he could not say.
There is a continuous drumbeat of questionable attempts to foster a sense of absolute certainty in investors that Reo is statistically efficacious.
Many longs have no idea the amount of risk they are taking with their life savings.